The Global Companion Diagnostics Market research report aims to provide an unbiased and a comprehensive outlook of the Global market to the readers. Analysts have studied the key trends defining the trajectory of the market. The research report also includes an assessment of the achievements made by the players in the Companion Diagnostics Market so far.
Exclusive offer: Up to 30% discount on this report
Buy the Latest Detailed Report @:
Abbott, Agilent Technologies, F. Hoffmann-La Roche Ltd, Biomerieux SA, and Qiagen NV and other for more company coverage please register for sample inquiry.
The growth of the global companion diagnostics market can be attributed to the rising focus on personalized medicine and co-development of drug and diagnostic technologies. In addition, rising cases of adverse drug reactions related to drugs, due to the lack of efficacy, drive the need for companion diagnostics. One of the major factors driving the growth of the companion diagnostics market is the increasing demand for personalized medicines and awareness about the same among the population. With companies increasing their collaborations for better biomarkers and diagnostics, in order to focus on cost regulations, there has been significant number of opportunities for its applications in indications, like cancer, cardiovascular and neurological disorders, etc.
Inquire for sample before purchase:
Scope of the Report
Companion diagnostic tests provide information that is essential for the safe and effective use of a corresponding drug or biological product. As per the scope of the report, the market studied has been segmented by technology, indications, and geography. By technology, the market studied has been further segmented into immunohistochemistry, polymerase chain reaction, in-situ hybridization, real time-polymerase chain reaction, gene sequencing, and other technologies.
In-situ Hybridization (ISH) Segment is Expected to Exhibit Fastest Growth Rate Over the Forecast Period
In-situ hybridization (ISH), especially fluorescence in-situ hybridization (FISH), is a reliable, reproducible, sensitive, and accurate procedure, which is less affected by tissue fixation and analytical variables, in comparison to immunochemistry and other techniques. It offers the benefit of simultaneous evaluation of morphology and gene amplification. FISH has been the method of choice for use in companion diagnostics for several cancer therapies, such as trastuzumab, lapatinib, and criotinib, which have been already approved by FDA and other therapies, like everolimus, ridaforolimus, bicatulamide, TBD, and other drugs, that are yet to obtain regulatory approval.
The global market for in-situ hybridization in CDx is growing because of technological advancements, like the recent development of bright-field in-situ hybridization techniques, chromogenic in-situ hybridization (CISH), and the automated silver-enhanced in-situ hybridization (SISH) for the determination of gene status. Thus, considering the aforementioned factors, the ISH segment is expected to exhibit growth over the forecast period.
Get Discount on this Report:
Influence of the Companion Diagnostics market report:
- Comprehensive assessment of all opportunities and risk in the Companion Diagnostics market.
- Companion Diagnostics market recent innovations and major events.
- Detailed study of business strategies for growth of the Companion Diagnostics market-leading players.
- Conclusive study about the growth plot of Companion Diagnostics market for forthcoming years.
- In-depth understanding of Companion Diagnostics market-particular drivers, constraints and major micro markets.
- Favorable impression inside vital technological and market latest trends striking the Companion Diagnostics market.
We Offer Customization On Report Based On Specific Client Requirement:
– Free country Level analysis for any 5 countries of your choice.
– Free Competitive analysis of any 5 key market players.
– Free 40 analyst hours to cover any other data point.
Irfan Tamboli (Sales)
Phone: + 1704 266 3234 | +91-750-707-8687
firstname.lastname@example.org | email@example.com